Cross-border network of personalised immunotherapies in the treatment of non-Hodgkin's lymphoma (Q4295764): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
||
| Property / contained in NUTS | |||
| Property / contained in NUTS: Haute-Garonne / rank | |||
Normal rank | |||
Revision as of 12:41, 17 June 2022
Project Q4295764 in France, Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Cross-border network of personalised immunotherapies in the treatment of non-Hodgkin's lymphoma |
Project Q4295764 in France, Spain |
Statements
1,343,659.2 Euro
0 references
2,067,168.0 Euro
0 references
65.0 percent
0 references
1 January 2018
0 references
31 December 2020
0 references
Consorci Institut d'Investigacions Biomèdiques August Pi i Sunyer
0 references
43°33'45.04"N, 1°25'34.57"E
0 references
41°58'13.30"N, 2°47'47.26"E
0 references
41°23'25.08"N, 2°9'12.46"E
0 references
42°45'15.95"N, 1°38'14.10"W
0 references
43°36'43.99"N, 1°23'51.29"E
0 references
In the era of personalised medicine, IMLINFO aims to create a repository of Non-Hodgkin Lymphoma (NHL) associated to a 3 dimension (3D) culture platform, that will allow the determination of efficacy of new immunotherapy treatments. 450-1050 new NHL cases are detected each year inside POCTEFA´s territory ; current treatments include a polychemotherapy backbone of variable efficacy often associated to significant side effects. IMLINFO gathers hospitals, research institutes, one pharmaceutical company and one technological company, to establish personalized immunotherapies that reactivate patient´s immune system, inducing tumor regression in the absence of chemotherapy. IMLINFO is a multidisciplinary team with experts in 3D culture and multicellular cultures, together with the characterisation of 3D structures and drug penetrance by next generation microscopy. Moreover, the pharmaceutical company integrated in IMLINFO has recognized experience in the development of small molecules as innovative immunotherapies, some of them already licensed to international pharmaceutical companies. Aiming to progress towards personalized medicine, the cross-border cooperation is mandatory for the collection of material of a significant number of NHL patients from each of the hospital in the cross-border territory, together with scientific and technological collaboration. (English)
0 references